Publicaciones en colaboración con investigadores/as de Hospital Universitario 12 de Octubre (16)

2023

  1. Recommendations by the Spanish Society of Rheumatology on risk management of biological treatment and JAK inhibitors in patients with rheumatoid arthritis

    Reumatologia Clinica, Vol. 19, Núm. 10, pp. 533-548

  2. Safety and effectiveness of bDMARDs during pregnancy in patients with rheumatic diseases: Real-world data from the BIOBADASER registry

    Reumatologia Clinica, Vol. 19, Núm. 9, pp. 500-506

2019

  1. Evaluation of 12 GWAS-drawn SNPs as biomarkers of rheumatoid arthritis response to TNF inhibitors. A potential SNP association with response to etanercept

    PLoS ONE, Vol. 14, Núm. 2

2017

  1. Recommendations for the evaluation and management of patients with rheumatic autoimmune and inflammatory diseases during the reproductive age, pregnancy, postpartum and breastfeeding

    Reumatologia Clinica, Vol. 13, Núm. 5, pp. 264-281

2016

  1. Replication of PTPRC as genetic biomarker of response to TNF inhibitors in patients with rheumatoid arthritis

    Pharmacogenomics Journal, Vol. 16, Núm. 2, pp. 137-140

2015

  1. FCGR polymorphisms in the treatment of rheumatoid arthritis with Fc-containing TNF inhibitors

    Pharmacogenomics, Vol. 16, Núm. 4, pp. 333-345

  2. Rheumatoid arthritis response to treatment across IgG1 allotype - anti-TNF incompatibility: A case-only study

    Arthritis Research and Therapy, Vol. 17, Núm. 1

2014

  1. Lack of replication of interactions between polymorphisms in rheumatoid arthritis susceptibility: Case-control study

    Arthritis Research and Therapy, Vol. 16, Núm. 1

  2. Lack of validation of genetic variants associated with anti-tumor necrosis factor therapy response in rheumatoid arthritis: A genome-wide association study replication and meta-analysis

    Arthritis Research and Therapy, Vol. 16, Núm. 2

2009

  1. Analysis of TNFAIP3, a feedback inhibitor of nuclear factor-κB and the neighbor intergenic 6q23 region in rheumatoid arthritis susceptibility

    Arthritis Research and Therapy, Vol. 11, Núm. 2

  2. Genetic variation in the nuclear factor κB pathway in relation to susceptibility to rheumatoid arthritis

    Annals of the Rheumatic Diseases, Vol. 68, Núm. 4, pp. 579-583

  3. Lack of association with rheumatoid arthritis of selected polymorphisms in 4 candidate genes: CFH, CD209, Eotaxin-3, and MHC2TA

    Journal of Rheumatology, Vol. 36, Núm. 8, pp. 1590-1595

  4. Rheumatoid arthritis does not share most of the newly identified systemic lupus erythematosus genetic factors

    Arthritis and Rheumatism, Vol. 60, Núm. 9, pp. 2558-2564

2008

  1. Association of interferon regulatory factor 5 haplotypes, similar to that found in systemic lupus erythematosus, in a large subgroup of patients with rheumatoid arthritis

    Arthritis and Rheumatism, Vol. 58, Núm. 5, pp. 1264-1274

2006

  1. Switching TNF antagonists in patients with chronic arthritis: An observational study of 488 patients over a four-year period

    Arthritis Research and Therapy, Vol. 8, Núm. 1

1999

  1. Risk of thrombosis in patients with antiphospholipid antibodies and factor V Leiden mutation

    Journal of Rheumatology, Vol. 26, Núm. 3, pp. 588-590